Ciba-Geigy Ltd. and Chiron Corp. said #Gen:ADDR they extended their offer for Connaught BioSciences Inc., #Cor:PAT valued #Gen:ACT at 866 million Canadian dollars -LRB-US$ 736 million-RRB- to Oct. 27.
The companies earlier said #Gen:ADDR they didn't want to #Cor:ACT raise their offer to #PersPron:ACT match a rival bid by Institut Merieux S.A. of C$ 37 a share, or C$ 942 million.
But they said #Gen:ADDR the C$ 30-a-share bid, which was due #Cor:ACT to #Cor:ACT expire Monday, may still be extended #Gen:ACT or varied .
Merieux, a vaccine manufacturer #Gen:ACT based #Cor:PAT in Lyon, France, is 51%-held by French state-owned Rhone-Poulenc S.A.
Ciba-Geigy is a major pharmaceutical concern #Gen:ACT based #Cor:PAT in Basel, Switzerland.
Chiron, another pharmaceutical concern, is #Gen:ACT based in Emeryville, Calif.
Connaught is a biotechnology research and vaccine manufacturing concern.
Institut Merieux's bid for Toronto-based Connaught has run into problems with the Canadian government, which told Merieux last week that it wasn't convinced #Gen:ACT that the proposed acquisition would be of ``net benefit'' to Canada.
Merieux officials are expected #Gen:ACT to meet with federal officials in Ottawa today to #Cor:ACT discuss #Cor:ADDR the decision.
